Clinical Trial Update: An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients. [Phase 2]

View source ↗

Summary

A Phase II open-label randomized trial comparing Thymoglobulin with Simulect for prevention of delayed graft function and acute rejection in renal transplant re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation
• Renal Allograft Rejection

Drugs mentioned

• Simulect (Basiliximab)
• Thymoglobulin (rabbit anti-thymocyte globulin)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Cadaveric Donor Renal Transplantation, Acute Renal Allograft Rejection | Phase 2 | Status: COMPLETED